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Abstract
Background: Recombinant human activated protein C (rhAPC) is associated with improved
survival in high-risk patients with severe sepsis; however, the effects of both lipopolysaccharide
(LPS) and rhAPC on the bronchoalveolar lavage fluid (BALF) proteome are unknown.
Methods: Using differential in gel electrophoresis (DIGE) we identified changes in the BALF
proteome from 10 healthy volunteers given intrapulmonary LPS in one lobe and saline in another
lobe. Subjects were randomized to pretreatment with saline or rhAPC.
Results: An average of 255 protein spots were detected in each proteome. We found 31 spots
corresponding to 8 proteins that displayed abundance increased or decreased at least 2-fold after
LPS. Proteins that decreased after LPS included surfactant protein A, immunoglobulin J chain,
fibrinogen-γ, α1-antitrypsin, immunoglobulin, and α2-HS-glycoprotein. Haptoglobin increased after
LPS-treatment. Treatment with rhAPC was associated with a larger relative decrease in
immunoglobulin J chain, fibrinogen-γ, α1-antitrypsin, and α2-HS-glycoprotein.
Conclusion: Intrapulmonary LPS was associated with specific protein changes suggesting that the
lung response to LPS is more than just a loss of integrity in the alveolar epithelial barrier; however,
pretreatment with rhAPC resulted in minor changes in relative BALF protein abundance consistent
with its lack of affect in ALI and milder forms of sepsis.
Background
Bacterial pneumonia and Gram negative sepsis (GNS) are
syndromes of complex pathogenesis with a high mortality
[1]. Although the pathophysiology of lung injury during
sepsis is complex, the host response to lipopolysaccharide
(LPS) is one of the early activators of the immune system
[2]. Later characteristics of GNS and pneumonia include
severe dysfunction of the alveolar-capillary barrier leading
to acute lung injury (ALI) and respiratory failure [3]. In
ALI, damage to the endothelium and alveolar epithelium
barrier results in plasma protein efflux into the alveolar
spaces that leads to hypoxemia and respiratory failure [4-
8]. GNS and ALI are also characterized by systemic activa-
tion of the acute phase response with elevation of acute
phase proteins in serum [9] and epithelial lining fluid
[10].
Infection agents and inflammatory agents are also
thought to induce coagulation by stimulating the expres-
sion of tissue factor on monocytes and endothelium, lead-
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ing to thrombin generation [11]. Activated protein C
(APC) is a natural anticoagulant that plays an important
role in coagulation homeostasis by inactivating the proco-
agulant factors Va and VIIIa, resulting in decreased
thrombin generation. rhAPC can improve lung function
after ALI by improving PaO2/FIO2 ratios, reducing micro-
vascular shunt fraction, decreasing peak airway pressures,
and reducing lung nitrotyrosine formation, even without
a significant anticoagulant effect [12]. Recombinant
human APC (rhAPC) is the only medication that has been
shown to reduce mortality in patients with severe sepsis
[13]. Although rhAPC is inactivates clotting factors Va and
VIIIa, there is increasing evidence that its beneficial effects
are not solely due to its anticoagulatory effect [14]. For
instance, APC has anti-apopotic effects [15,16], reduces
nuclear translocation of nuclear factor κ-B [17], and can
inhibit leukocyte adhesion by inhibiting leukocyte-
induced arteriolar rolling [18]. However, it is unknown
how rhAPC affects LPS-induced changes in the lung pro-
teome.
Proteomics and difference gel electrophoresis (DIGE) per-
mit simultaneous assessment of alterations in large num-
bers of proteins [19]. Proteomics has been used to
describe LPS-induced changes in protein expression in
animal models and human cell lines [20-25], and DIGE
has recently been used to identify serial BALF proteome
changes in ALI patients [26]. A limitation of previous
studies of the human lung proteome has been the lack of
an internal control which can limit the interpretation of
findings for two reasons (1) the majority of BALF proteins
are also plasma proteins [27] and (2) there is a large inter-
subject variability in expression of proteins [28]. In this
study, we used a proteomic approach to identify changes
in the lung proteome that result from intrapulmonary LPS
with and without administration of rhAPC. The approach
was uniquely powerful because each subject had saline
instillation in a control lobe to eliminate inter-subject and
temporal variability. This study provides insight not only
into the alterations in pulmonary proteins induced by
exposure to LPS, such as occurs with Gram negative pneu-
monia, but also identifies the changes in bronchoalveolar
lavage protein profiles associated with administration of
rhAPC.
Methods
Study subjects
All subjects were admitted to the General Clinical
Research Center (GCRC) at the University of Colorado
Hospital. Approval for this study was obtained from the
Colorado Multiple Institutional Review Board, and
informed consent was provided according to the Declara-
tion of Helsinki. The subjects (N = 10) were randomly
selected from a parent study designed to examine LPS-
induced pulmonary neutrophilic inflammation with and
without rhAPC (see [29] for details). The parent study
subjects (N = 16) were non-smokers, ages 18–40 years,
randomized to receive either rhAPC (drotrecogin alfa
[activated]; 24 mcg/kg per hour) or normal saline (the
solution for drotrecogin alfa [activated]) starting 2 hours
before the initial bronchoscopy and continuing for 16
hours. The infusion of rhAPC or placebo was discontin-
ued 2 hours prior to the second bronchoscopy to lessen
the risk of hemorrhage resulting from anticoagulant prop-
erties of rhAPC. The volunteers were premedicated with
one double-strength trimethoprim/sulfamethoxazole tab-
let 12 hours and 1 hour before bronchoscopy. Any subject
with a history of sulfa allergy was given 2 doses of oral
amoxicillin (500 mg), separated by 8 hours. Subject char-
acteristics are listed in Table 1.
At the time of the first bronchoscopy, 10 mL saline was
instilled into a lung subsegment (either the right middle
lobe or lingula) followed by instillation of the test dose of
reference endotoxin (4 ng/kg in 10 mL saline) into the
contralateral lung. The subjects were randomized to left or
right lungs for endotoxin or saline instillation. Following
reconstitution of the endotoxin, a quantitative Limulus
amebocyte lysate test was performed to verify the proper
reconstitution and dosage of endotoxin. A second bron-
choscopy was performed 16 hours after the initial bron-
choscopy. At the time of the second bronchoscopy, both
the endotoxin and placebo-instilled subsegments were
lavaged with 150 mL normal saline.
Processing of samples
The cell-free supernatants were frozen at -80°C. Total pro-
tein in BALF was determined by the bicinchoninic acid
(BCA) assay and employed bovine albumin standards
(Pierce, Rockford, IL). BALF aliquots of 3 ml each were
dialyzed in 300 MWCO dialysis tubing (Pierce, Rockford,
IL) against 4 L of 10 mM Tris-HCl pH 8.0 overnight at
4°C. The Tris-HCl was changed once after two hours. The
dialyzed samples were freeze-dried and then resuspended
in 7 M urea, 2 M thiourea, 1 M Tris-HCL pH 8.0, and 4%
CHAPS. All reagents were supplied by Sigma Chemical
Co. (St. Louis, MO) unless otherwise noted.
Table 1: Baseline characteristics of the subjects
Control rhAPC
N (f/m) 5 (4/1) 5 (2/3)
Age (years) 28 ± 8 27 ± 3
BALF protein (μg/mL) saline treated lobe 112 ± 66 80 ± 32
BALF protein (μg/mL) LPS treated lobe 456 ± 462 595 ± 235
Means and standard deviation (SD) of the groups are reported; there 
were no significant differences between groupsBMC Pulmonary Medicine 2009, 9:20 http://www.biomedcentral.com/1471-2466/9/20
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Differential in-gel electrophoresis (DIGE)
For DIGE, 5 ug of protein was independently labeled with
Cy3 and Cy5 dye as per the manufacturer's protocol
(Amersham/GE). Following labeling both saline- and
LPS-instilled BALF samples for each subject were com-
bined and analyzed on the same gel. A dye swap was used
for all samples to avoid labeling bias (i.e. for each subject
a DIGE gel was run with control (saline) BALF sample
labeled with Cy3 labeled and LPS sample labeled with
Cy5 and a second DIGE gel was run with control sample
labeled with Cy5 and a LPS sample labeled with Cy3).
Dye labeling occurred in the dark at 37°C and was
stopped with 7 M urea, 2 M thiourea, 4% CHAPS, DTT
130 mM, and 2% biolytes. For protein spot identification,
10 μg of each sample was pooled and then 500 μg total
used for subsequent steps (preparative gel).
The combined samples were applied to 24 cm immobi-
lized pH gradient (IPG) strips (BioRad) with a pH 3–10
linear gradient. Rehydration took place at 50 V for 17 h
and at 20°C in a Protean isoelectric focus (IEF) Cell (Bio-
Rad). First dimension isoelectric focusing was carried out
at 20°C in a Protean IEF Cell using the following proto-
col: 250 V for 15 min; 10,000 V for 3 hours; then over-
night at 10,000 V for 60,000 volt-hours followed by a 500
V hold. After isoelectric focusing, strips were equilibrated
by agitating for 10 minutes in 50 mM Tris-HCl, pH 8.8, 6
M urea, 30% (v/v) glycerol, 2% (w/v) sodium dodecyl sul-
fate (SDS), 650 mM DTT and then agitating for10 minutes
in 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% (v/v) glycerol,
2% (w/v) SDS, 1.27 M iodoacetamide. The strips were
next loaded onto a 24 × 24 cm 12% polyacrylamide gel
using low fluorescence glass plates and subjected to an
electric field in a Protean Plus Dodeca cell (BioRad; 4°C
at a constant 20 mA per gel, 18 hours in a running buffer
containing 25 mM Tris, 192 mM glycine, and 0.1% (w/v)
SDS). The preparative gel was stained with Sypro Ruby
(BioRad) as previously described [10]. After electrophore-
sis, proteins were digitally imaged using a Typhoon Varia-
ble Mode Imager (GE Healthcare).
Image analysis
Images were analyzed using DeCyder 5.0 (GE Health-
care). Spot volumes (Area × Density) were calculated for
each spot and averaged across the gel. The volume ratios
for the control and LPS BALF were calculated for each
spot. Spots that increased or decreased at least two-fold in
both dye swap gels in at least two subjects were selected
for identification.
Protein identification
Protein identifications were made using a pooled prepar-
ative gel and stained with Sypro Ruby (Biorad). Spots of
interest were excised using an Ettan Spot Picker (GE
Healthcare) and digested overnight with trypsin using an
automated basic protocol and Ettan Digester (GE Health-
care). Extracted peptides were subsequently dried to
reduce volume and remove organic solvent. Peptides were
chromatographically resolved on-line using a C18 col-
umn and analyzed using a 6340 LCMS ion trap mass spec-
trometer (Agilent Technologies, Palo Alto, CA) in the
National Jewish Health Proteomics Facility. The mass
spectrometry system includes a high performance liquid
chromatography (HPLC) chip interface (Agilent Technol-
ogies). Raw data was extracted and searched using the
Spectrum Mill search engine (Rev A.03.03.038 SR1, Agi-
lent Technologies, Palo Alto, CA). "Peak picking" is per-
formed within SpectrumMill with the following
parameters: signal-to-noise is set at 25:1, a maximum
charge state of 4 is allowed (z = 4), and the program is
directed to attempt to "find" a precursor charge state. Dur-
ing searching the following parameters were applied: IPI
human database (IPI Human release 3.28, 16-APR-2007),
carbamidomethylation as a fixed modification, trypsin,
maximum of 1 missed cleavage, precursor mass tolerance
+/- 1.7, product mass tolerance +/- 0.7, and maximum
ambiguous precursor charge = 3. Data were evaluated and
protein identifications were considered significant if the
following confidence thresholds were met: minimum of 2
peptides per protein, protein score > 20, individual pep-
tide scores of at least 7, and Scored Peak Intensity (SPI) of
at least 70%. The SPI provides an indication of the percent
of the total ion intensity that matches the peptide's MS/
MS spectrum. A reverse (random) database search was
simultaneously performed and manual inspection of
spectra was used to validate the match of the spectrum to
the predicted peptide fragmentation pattern, hence
increasing confidence in the identification. Standards are
run at the beginning of each day and at the end of a set of
analyses for quality control purposes.
Statistical analysis
Protein spots for the BALF proteome from the LPS-
instilled lobe were matched to the BALF proteome of the
saline-instilled lobe. JMP version 7.0 for Macintosh (SAS
Institute, Cary, NC) was used to compute medians, means
and standard deviations for relative increases or decreases
in protein abundance. Clusters of protein spots with iden-
tical identifications were grouped together for analysis
since they all had nearly identical relative changes in
abundance. A non-parametric test (Wilcoxon Matched-
Pairs Rank-Sum Test) was used to determine if relative
changes were significantly different at a predetermined
significance level of P < 0.05.
Results
BALF protein concentrations were significantly higher in
lobes exposed to LPS (526 ± 110 μg/ml) compared to
those that received saline (90 ± 16 μg/ml; P < 0.001);
however, there were no significant differences in BALFBMC Pulmonary Medicine 2009, 9:20 http://www.biomedcentral.com/1471-2466/9/20
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protein concentration in subjects who received rhAPC ver-
sus those who received saline. An average of 255 spots
(range 204–307) were identified and used for analysis for
each gel. A representative gel is shown in Figure 1. There
were no significant differences in the number of spots
automatically detected in subjects that received saline ver-
sus rhAPC. Relative changes in protein expression were
independent of dye labeling for nearly all proteins (Figure
2). Protein spots that had relative increases or decreases of
at least 2-fold at P < 0.05 in at least six of the subjects were
picked for identification (Table 2). Most proteins were
associated with a train of spots that yielded identical iden-
tifications by mass spectrometry. For example, IgJ protein
was represented by three spots. In all cases, these protein
spots behaved as a group: e.g. when one protein spot
increased two-fold all other spots in the group increased
approximately two-fold. Both median and mean intensity
changes were reported for the group as a whole (Table 3)
and also broken down by whether they received saline or
rhAPC (Table 4). We have previously identified other pro-
teins such as transferrin, clusterin, serum amyloid protein,
hemoglobin α-2, and α-2 HS-glycoprotein that were ele-
vated in patients with acute lung injury [10]; however,
these proteins were not differentially abundant in this
study. The following describes the proteins that we identi-
fied as being differentially abundant in BALF with LPS-
instillation:
Haptoglobin (HP)
We detected 5 protein spots for haptoglobin in all 10 sub-
jects. In 9 of 10 subjects there was an increase in hap-
toglobin protein spot intensity in the LPS lobe, with a
median increase of 3.18-fold (95% range 1.3–25.9-fold)
in the subjects who received saline versus a 2.07-fold
increase (95% range 0.25–17.9-fold) in subjects that
received rhAPC (P = 0.053). Representative database
results for HP were as follows: Accession number:
IPI00641737, Score: 41.37, 3 peptides (scores 20,12, and
9, and SPIs 98.3, 86.6, and 96.5 respectively), and 6%
total coverage.
Surfactant Protein A (SP-A)
There were 5 protein spots detected for SPA in 9 of 10 sub-
jects. One subject in the control group did not have SP-A
detectable in either the control or LPS instilled lobe BALF.
In 7 of 9 of the subjects there was a decrease in SP-A pro-
tein spot intensity in the LPS lobe with a median decrease
of 1.94-fold (95% range 0.8–44-fold decrease) in the sub-
jects who received saline versus a median 20.78-fold
decrease (95% range 0.3–78-fold decrease) in subjects
that received rhAPC (P = NS). Database results for SP-A
were as follows: Accession number: IPI00012889, Score:
45.53, 2 peptides with multiple spectra (scores 24 and 22,
and SPIs 96% and 97.5% respectively), and 11% total cov-
erage.
Immunoglobulin J chain (IgJ)
There were 3 protein spots detected for IgJ in 8 of 10 sub-
jects. Two subjects in the control group did not have IgJ
detectable in either the control or LPS instilled lobe BALF.
All 8 of the remaining subjects had a decrease in IgJ pro-
tein spot intensity after LPS with a median decrease of
2.55-fold (95% range 0.3–3.6 fold decrease) in the sub-
jects who received saline versus a median 14.06-fold
decrease (95% range 3.8–48.5-fold decrease) in subjects
that received rhAPC (P < 0.001). Database results for IgJ
were as follows: Accession number: IPI00178926, Score:
34.68, 3 peptides with multiple spectra (scores 17, 9.45
and 7.9, and SPIs 96%, 97%, and 95% respectively), and
16% total coverage.
Albumin variant
There were 3 protein spots for an albumin fragment
detected in 8 of 10 subjects. Although the calculated mass
of this protein was 71.6 kD and pI 6.33, the observed
mass was 42 kD and the pI 5.3 suggesting that there was a
post-translational modification. Two subjects in the
group that received saline did not have the albumin frag-
ment detectable in either the control or LPS instilled lobe
BALF. In 7 of 8 of the subjects there was a 2-fold decrease
in albumin fragment protein spot intensity after LPS with
a median decrease of 1.3-fold in the subjects who received
Table 2: Characteristics of proteins that significantly changed in the lobe treated with saline vs LPS
Observed
Protein Abbreviation Accession # Score Peptides Coverage Identification Method Mass (kD) pI
Alpha 2-HS glycoprotein αHSG IPI00020091 52 4 19% LCMS 68 4.8
α1-antitrypsin AAT IPI00553177 62 5 14% LCMS 43 5.7
Albumin Alb IPI00022434 108 8 11% LCMS 42 5.7
Fibrinogen γ Fg IPI00021891 84 7 37% MALDI 60 5.8
Haptoglobin HP IPI00641737 41 3 6% LCMS 44 5.5
Immunoglobulin IgG-l IPI00641082 50 5 20% LCMS 26 7.5–8.1
Immunoglobulin J chain IgJ IPI00178926 35 3 16% LCMS 29 4.6
Surfactant Protein A SPA IPI00012889 46 2 11% LCMS 35 5.0BMC Pulmonary Medicine 2009, 9:20 http://www.biomedcentral.com/1471-2466/9/20
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saline versus a 3.6-fold decrease in subjects that received
rhAPC (P = 0.05).
α1-antitrypsin (AAT)
There were 3 protein spots for AAT detected in all 10 sub-
jects. In 8 of the subjects there was a decrease in AAT pro-
tein spot intensity in the LPS instilled lobe. Two of the
subjects treated with rhAPC had a less than 2-fold
decrease in AAT. The median decrease in AAT was 1.35-
fold (95% range 0.4–3.4-fold decrease) in the subjects
who received saline versus a 2.55-fold (95% range 1.9–
12.8-fold decrease) in subjects that received rhAPC (P <
0.05). Database results for ATT were as follows: Accession
number: IPI00553177, Score: 62.23, 5 peptides from mul-
tiple spectra (scores 18, 14, 11, 10, and 10 and SPIs 86%,
79%, 74%, 87%, and 75% respectively), and 14% total
coverage.
Fibrinogen-γ (Fγ)
There was 1 protein spot for Fg detected in all 10 subjects.
In 9 of the subjects there was a decrease in Fγ protein spot
intensity after LPS, with a median decrease of 1.3-fold
(95% range 0.7–7.0 fold decrease) in the subjects who
received saline versus a 1.87-fold decrease (95% range
.1.2–4.7 fold decrease) in subjects that received rhAPC (P
< 0.01). Fγ was identified as previously described [10].
α2-HS-glycoprotein (αHSG)
There were 3 protein spots detected for αHSG in all 10
subjects. All of the subjects had a decrease in αHSG pro-
tein spot intensity in the LPS-instilled lobe with a median
decrease of 1.36-fold (95% range 0.7–7.0-fold decrease)
in the subjects who received saline versus a 2.74-fold
decrease (95% range 1.2–15.1-fold decrease), in subjects
that received rhAPC (P < 0.05). Database results for aHSG
were as follows: Accession number: IPI00020091, Score:
52.34, 4 peptides from multiple spectra (scores 19, 14, 11,
and 8 and SPIs 96%, 96%, 81%, and 71% respectively),
and 19% total coverage.
Immunoglobulin G (IgG)
There were more than 10 protein spots detected for IgG in
all 10 subjects. In 4 of 5 of the control subjects there was
no change in IgG light chain (IgG-l) protein spot intensity
after LPS with a median increase of 1.0-fold. All 5 subjects
given rhAPC had a greater than 2-fold decrease in IgG-l
protein spot intensity of 3.1-fold (P = 0.003 compared to
control group). IgG heavy chain (IgG-κ) was detected in
all 10 of 10 subjects; however, for unclear reasons, labe-
ling of the proteins with Cy3 was 10-fold more efficient
than with Cy5. Thus, the dye swap revealed that DIGE is
unreliable for detecting differences in this protein.
Other proteins
There is a substantial amount of albumin in BALF. How-
ever, there were no relative changes in albumin abun-
dance after LPS other than the fragment discussed above.
Unlike one of our previous studies of ALI subjects [10],
there were no significant differences in expression of α1-
acid glycoprotein.
Table 3: Magnitude of protein changes in saline versus LPS treated lobe
Median (Mean) fold change in LPS treated lobe compared to saline treated lobe
Protein decrease increase
Alpha 2-HS glycoprotein 2.38 (3.3)
α1-antitrypsin 2.4 (3.0)
Albumin 2.4 (2.8)
Fibrinogen γ 1.6 (1.6)
Haptoglobin 2.58 (5.76)
Immunoglobulin 2.0 (2.2)
Immunoglobulin J chain 3.79 (9.6)
Surfactant Protein A 2.0 (14.3)
Note that each patient was his/her own control and that changes are expressed as relative abundance of the protein in the proteome of the LPS 
treated lobe compared to relative abundance of the protein in the proteome of the saline treated lobe
Table 4: Median (mean) relative abundance of BALF proteins in 
saline versus LPS treated lobe in control and rhAPC treated 
subjects
Protein Control rhAPC P
Alpha 2-HS glycoprotein -1.36 (-2.2) -2.74 (-4.3) < 0.05
α1-antitrypsin -1.35 (-1.2) -2.55 (-3.7) < 0.05
Albumin -1.3 (-2.2) -3.6 (-4.1) NS
Fibrinogen γ -1.3 (-1.1) -1.87 (-2.2) < 0.01
Haptoglobin 3.18 (8.2) 2.06 (3.3) NS
Immunoglobulin J chain -2.55 (-1.7) -14.06 (-17.0) < 0.001
Surfactant Protein A -1.94 (-6.0) -20.78 (-22.5) NS
Negative fold changes represent decreases while positive fold changes 
represent increases; P values calculated using Wilcoxan-Rank-SumBMC Pulmonary Medicine 2009, 9:20 http://www.biomedcentral.com/1471-2466/9/20
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Discussion
This study demonstrates that instillation of intrapulmo-
nary LPS results in significant changes in the relative
abundance of selected proteins. The approach we used is
unique because to our knowledge it is the only BALF pro-
teomics study in which the research subject is his/her own
control, thereby greatly decreasing the "noise" of biologic
variation. The observed changes in relative abundance are
unlikely to be due to external factors for the following rea-
sons: (1) scanning protocols were optimized to avoid flu-
orescent saturation during image analysis (saturation
leads to underreporting of differences of abundant pro-
teins); (2) we performed dye-swap experiments for all
subjects to eliminate the potential bias of differential labe-
ling with Cy3 versus Cy5 dye; (3) the direction of change
in relative abundance and the magnitude of change were
similar for all studied proteins. Furthermore, intersubject
and temporal variability were eliminated by using a saline
instilled lobe as an internal control for each subject. It is
possible but unlikely that the observed changes in relative
abundance were due to technique (the bronchoscopist
and proteomics technicians were blinded to group), ran-
dom chance (some of the findings have been reported in
clinical studies of LPS and ALI), or that saline instillation
induced changes that masked LPS-induced changes. Thus,
the most likely explanation for the observed changes is
true biologic changes in the pulmonary proteome in
response to LPS. Although we confirmed that the largest
biologic factor that affects the absolute content of protein
in the BALF is a breakdown in the alveolar-capillary bar-
rier [30], the relative abundance of the majority of high
molecular weight proteins in the lung proteome did not
change suggesting that the observed relative changes in
abundance may be due to factors other than breakdown
in the alveolar-capillary barrier.
Although this study was conducted under uniform exper-
imental conditions and used internal controls, our find-
A pseudocolor difference gel electrophoresis (DIGE) image from a representative subject (subject 19) Figure 1
A pseudocolor difference gel electrophoresis (DIGE) image from a representative subject (subject 19). Proteins 
from the saline treated lung lobe were conjugated to Cy3 (shown in green) and protein from the LPS treated lobe was conju-
gated to Cy5 (shown in red). Equal amounts of protein were loaded onto the gel from each condition. Green spots represent 
proteins that were relatively higher in the saline treated lobe; red spots indicate proteins that were relatively higher in LPS 
treated lobe; yellow spots represent proteins that were expressed at relatively similar levels. Each of the circled spots was 
identified by mass spectrometry and labeled according to identification as follows: haptoglobin (HP), surfactant protein A 
(SPA): immunoglobulin J chain (IgJ), α1-antitrypsin (AAT), fibrinogen-γ (Fγ), α2-HS-glycoprotein (αHSG), immunoglobulin G 
(IgG).BMC Pulmonary Medicine 2009, 9:20 http://www.biomedcentral.com/1471-2466/9/20
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ings can be contrasted with other uncontrolled lung
proteomic studies of health and sick individuals in a clin-
ical setting. For instance, Wattiez et al [31] studied the
BALF proteome from 5 healthy subjects, 3 patients with
idiopathic pulmonary fibrosis (IPF), and 2 patients with
hypersensitivity pneumonitis. Similar to our findings,
these investigators were able to detect relative decreases in
the intensity of SP-A in patients with IPF and HP, but
found relative increases in the intensity of proteins, such
as transferrin, transthyretin, α1-AT, and immunoglobulin.
The IPF and hypersensitivity pneumonitis patients also
demonstrated numerous spots corresponding to the N-
terminal sequences of haptoglobin. In another study of 8
healthy children and 17 children with cystic fibrosis, there
was increased intensity of α1-AT and lower molecular
weight isoforms of SP-A [32]. In an analysis of BALF col-
lected from seven healthy children undergoing diagnostic
operations and 10 children with malignancies, fever, and
chest infiltrates, the sick children were noted to have large
increases in intensities of α1-AT and hemoglobin,
decreases in transthyretin, but no changes in SP-A, trans-
ferrin, or immunoglobulins [33]. We have also previously
reported that patients with acute lung injury (ALI) have
changes in SP-A and acute phase proteins, such as hap-
toglobin and α1-AT [10]. Relative decreases in BALF SP-A
in ALI patients have also been reported in other studies
and have prognostic value [34,35]. In all of these studies
it was unclear whether these changes were biased because
there were no internal controls of the lung proteome in an
unperturbed state. Our investigation used each subject as
his/her own control, thus these problems were elimi-
nated. However, our results did show similarities in some
of the lung proteome changes (e.g. LPS instillation was
associated with relative decreases in SP-A and increases in
haptoglobin).
One of the hallmarks of nearly all of these forms of lung
injury is loss of size selectivity of the alveolar-capillary
barrier [36] which causes high MW proteins, including
albumin, transferrin, and immunoglobulin, to leak from
plasma resulting in an increased concentration of protein
in the airspaces [7]. The 6-fold increase in total protein
concentration that we observed in the LPS instilled lobe is
consistent with these findings; however, a change in the
alveolar epithelial barrier cannot explain relative changes
in protein abundance for selected proteins because the
majority of larger proteins (e.g. most albumin variants,
IgG) did not show changes in relative abundance in the
LPS-instilled lobe. The most likely explanation for the lack
of change in relative abundance of the majority of these
Representative dye swap experiment shows that changes in relative protein expression are not due to differential labeling for  Cy3 or C5 Figure 2
Representative dye swap experiment shows that changes in relative protein expression are not due to differ-
ential labeling for Cy3 or C5. (A) Proteins from the saline treated lobe were conjugated to Cy3 (shown in green) and pro-
tein from the LPS treated lobe were conjugated to Cy5 (shown in red). (B) Proteins from the saline treated lobe were 
conjugated to Cy5 (shown in red) and protein from the LPS treated lobe were conjugated to Cy3 (shown in green). Relative 
changes in protein expression were of identical direction and similar magnitude regardless of which dye was used to label pro-
teins.BMC Pulmonary Medicine 2009, 9:20 http://www.biomedcentral.com/1471-2466/9/20
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proteins is that the DIGE approach we used only measures
larger (>10 kD) proteins, thus low molecular weight pro-
teins did not contribute to the analysis and loss of size
selectivity of the alveolar-epithelial barrier became less
relevant. Other limitations to the DIGE procedure include
a bias towards detecting high and medium abundant pro-
teins and an inability to quantitate proteins that are insol-
uble or do not stain (see review [19]). Since no
experimental technique can detect or quantitate all pro-
teins at all concentrations, we acknowledge that there may
be changes in the proteome that could have been missed
by this technique.
An alternative to the loss of alveolar-capillary barrier
integrity explanation is the hypothesis that LPS directly
alters lung metabolism of specific proteins. Supporting
this hypothesis are animal models demonstrating that
intrapulmonary LPS induces lung mRNA expression of
serum amyloid protein, β-2 glycoprotein-1, α-2 glycopro-
tein 1, and α-2 HS-glycoprotein; however, this response is
complicated by systemic mediators (e.g. IL-6) that may
also influence the expression of these proteins in the liver
[37]. Indeed an increase in systemic acute phase proteins
is one of the hallmark responses to inflammation [38]. In
our experimental model, the use of an internal control
(saline instilled lobe) should correct for these systemic
responses.
One example of a "plasma" protein whose metabolism
can be altered in the lung itself is haptoglobin. Hap-
toglobin is well known to complex with hemoglobin and
is metabolized in the hepatic reticuloendothelial system;
however, haptoglobin also has antioxidant and antimi-
crobial activity and plays a role in host defense responses
to infection and inflammation, acting as a natural antago-
nist for receptor-ligand activation of the immune system
[39]. The lung epithelium is a major source of extra
hepatic haptoglobin gene expression and can be induced
by LPS [40]. Although a proteomics approach cannot dif-
ferentiate the sites of origins of proteins, we observed a
relative increase in haptoglobin in the LPS-instilled lobe
suggesting that the source might be from pulmonary ori-
gin. Surprisingly, there have been few studies of the role of
haptoglobin in the lung [41] suggesting that the role of
this protein in the lung injury response needs further
investigation.
Unlike haptoglobin, SP-A has a well-described pulmonary
origin from type II epithelial cells. Our observations of a
relative decrease in SP-A are consistent with many find-
ings in lung injury studies in humans. For instance, pul-
monary SP-A has been previously shown to be depressed
in patients with acute lung injury [10,34] and plasma SP-
A has been shown to have prognostic value [35]; however,
two studies of rats reported an increase in SP-A after LPS
[42,43], and a study of human edema fluid SP-A in ALI
patients did not find that SP-A had prognostic implica-
tions [35]. Furthermore, impairment of SP-A function
appears to increase over time from onset of ALI [44].
These studies highlight that it is important to consider the
animal model (e.g. mouse/rat/human), sampling tech-
nique (BALF/edema fluid), and time course when inter-
preting results. Despite this, the majority of evidence
suggests that SP-A is decreased in ALI. The mechanisms by
which LPS down regulates SPA is unknown, but may be
due to binding and clumping to the lipid portion of LPS
[45] or enhanced clearance from excess nitration [46].
One systemic protein that may have immune implications
in the lung is IgJ. IgJ is a linker protein for IgM and IgA,
but not IgG. It is expressed in lung; however, most expres-
sion is in lymphocytes (Novartis GNF SymAtlas data-
base). We observed changes in relative abundance of IgJ
protein suggesting that there may be a decrease in relative
abundance of IgA or IgM immediately after LPS exposure.
Although not well studied in the lung, one explanation
could be due to binding of these proteins to known recep-
tors on airway epithelial cells [47].
Fibrin deposits are a major hallmark of lung injury and
local fibrin consumption through activation of coagula-
tion occurs in lung injury. We observed a relative decrease
in fibrinogen-γ in the LPS-instilled lobes compared to the
saline-instilled lobes. Treatment with rhAPC was associ-
ated with slightly larger relative decreases in fibrinogen-γ
in the LPS-instilled lobes, possibly due to rhAPC's PAI-1
inhibiting effects and restoration of the deficient clearing
of fibrin. In humans there is an inverse relationship
between fibrinogen and APC [48], thus rhAPC infusions
may lead to a relative decrease in fibrinogen concentra-
tions with the lung. In heatstroke models, there have been
conflicting results with a rat model showing improved
fibrinolysis [49], but no change in fibrinolysis in a
baboon heatstroke model [50]. Furthermore, in septic
humans there were no significant changes in fibrinogen
with rhAPC [51]. The role of rhAPC with other acute
phase reactants such as antitrypsin is unclear since AAT
inhibits APC activity [52], although this is not through the
37 loop of APC [53].
The otherwise modest changes that we observed in the
lung proteome of rhAPC patients is consistent with other
studies that have found minimal differences in volunteers
given intravenous LPS and rhAPC [11] as well as clinical
studies in patients with severe sepsis but low risk of death
[54]. The lack of reduction in total BALF protein increase
in rhAPC-pretreated patients is also consistent with some
[55] but not all [56] mouse models of LPS induced lung
injury. In clinical studies, the beneficial role of rhAPC has
been most marked in patients with severe sepsis [57];BMC Pulmonary Medicine 2009, 9:20 http://www.biomedcentral.com/1471-2466/9/20
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however, the volunteers in this study were unlikely to
have had the severe systemic changes that occurred in
these patients. Furthermore, rhAPC is not an effective
treatment for acute lung injury [58]. The experimental
model in this study is one of acute lung (more similar to
pneumonia). Thus, modest changes that we observed in
the subjects who received rhAPC versus the saline should
not be generalizable to its role of rhAPC in severe sepsis.
Conclusion
Instillation of LPS into human lung results in stereotypi-
cal patterns of increased or decreased relative abundance
of selected proteins; however, the magnitude of these
changes varies among individuals. These observations are
particularly relevant because each subject served as his/her
control, thus eliminating intersubject variability. The rela-
tive changes in the selected proteins suggest that LPS
induces specific metabolic changes in the lung besides just
a disruption in the alveolar epithelial barrier. Lung spe-
cific alterations in some of these proteins (e.g. SP-A and
haptoglobin) could serve as targets for novel therapies in
future research; however, rhAPC treatment was associated
with only modest changes in the LPS response, consistent
with its lack of clinical benefit in ALI or modest sepsis.
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